This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegfried, J. M. Articles by Landreneau, R. J. Search for Related Content PubMed PubMed Citation Articles by Siegfried, J. M. Articles by Landreneau, R. J.

Association of Immunoreactive Hepatocyte Growth Factor with Poor Survival in Resectable Non-Small Cell Lung Cancer¹

Departments of Pharmacology [J. M. S., P. S-K.], Biostatistics [L. A. W.], and Dental Public Health, School of Dental Medicine [R. J. W.]; Section of Thoracic Surgery [R. J. L.]; and University of Pittsburgh Cancer Institute [J. M. S.], University of Pittsburgh, Pittsburgh, Pennsylvania 15261; and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 [J. R. T.]

We have shown previously that hepatocyte growth factor (HGF), which is produced by lung fibroblasts, is a potent mitogen and motogen for both normal and neoplastic bronchial epithelium, and that expression of the HGF receptor, the c-met proto-oncogene protein, is uniformly found in the human bronchial epithelium and in non-small cell lung carcinomas (NSCLCs; P. Singh-Kaw et al., Am. J. Physiol., 268: L1012–L1020, 1995). Yamashita et al. have reported an association of HGF with poor survival in invasive ductal carcinoma of the breast (Cancer Res., 54: 1630–1633, 1994). There are few prognostic markers for lung cancer, and the high recurrence rate for stage I lung cancer suggests the frequent presence of undetectable tumor burden in such patients. Criteria are needed to evaluate these patients for risk of recurrence. We have now evaluated whether HGF present in resectable lung tumors has prognostic significance. In this study, 56 primary NSCLCs, mainly adenocarcinomas, were examined for presence of HGF by quantitative Western blot. These tumors consisted of tissue from 34 stage I patients, 9 stage II patients, and 13 stage III_a patients who underwent curative resection for primary NSCLC. Extracts of whole tumor tissue were analyzed after separation of proteins by electrophoresis and transfer of proteins to nitrocellulose membranes. Immunoreactive (ir)-HGF was visualized by reaction with a polyclonal anti-HGF antiserum and quantitated by densitometry. Lung tumor content of ir-HGF varied widely among individuals. Median ir-HGF content in tumor extracts was 15.3 ng/40 µg of tumor protein; mean ir-HGF was 27.2 ng/40 µg of tumor protein. The median and mean ir-HGF were both significantly higher in tumor tissue from patients who suffered a recurrence during the follow-up period compared with those with no evidence of residual disease; this was true of all patients (P = 0.0001) and stage I patients analyzed separately (P = 0.002). Analysis of survival curves indicated that ir-HGF levels higher than the median were associated with poor overall survival (P < 0.03). Univariate analysis showed three factors related to poor overall survival in this set of patients: ir-HGF, tumor (T) status (a measure of primary tumor size and extent), and age. Nodal (N) status and stage were only marginally related to overall survival, most likely because the majority of the patients in the study were stage I. N status, stage, and T status were related to disease-free survival, however. Multivariate Cox analysis showed that ir-HGF, T status, and age independently had a negative impact on overall survival. ir-HGF was a strong independent negative prognostic indicator (P = 0.0001) with a relative risk of 1.022 per unit of ir-HGF (ng/40 µg of protein). This demonstrates that, in this group of patients, the relative risk of ir-HGF content increased continuously as ir-HGF increased, and exceeded 10 at units of ir-HGF of 100 or more. In comparison, in this group of patients, the relative risk of a T status greater than 1 was 4.75 and that of age greater than 65 was 3.95. The combined negative effect of a T status greater than 1 and elevated ir-HGF on survival was also highly pronounced (P < 0.005). In addition, elevated ir-HGF had a negative impact on survival when patients were stratified by stage or N status. Stage I patients with high ir-HGF values had a worse outcome than stage II or stage III_a patients with low ir-HGF values. Elevated ir-HGF was strongly associated with poor outcome for resectable NSCLC patients as a group, and also identified stage I patients with poor outcome, indicating that it could be a useful indicator of risk of relapse and death in patients who have early lung cancer. The impact of elevated ir-HGF was especially prominent in patients whose T status was greater than 1, suggesting that patients with both risk factors who are stage I should be treated as aggressively as stage III_a patients. Thus, measurement of ir-HGF could be a useful prognostic indicator for both early and advanced NSCLC patients.

¹ This work was supported by a grant from the Charlotte Geyer Foundation and Grant R01 CA50694 from the National Cancer Institute (to J. M. S.), Grant P20 CA58235 from the National Cancer Institute to the University of Pittsburgh Cancer Institute, and Grant R01 CA45745 from the National Cancer Institute (to J. R. T.).

² To whom requests for reprints should be addressed, at Department of Pharmacology, University of Pittsburgh, E1340 Biomedical Science Tower, Pittsburgh, PA 15261. Phone: (412) 648-1942; Fax: (412) 648-1945.

³ Present address: Department of Surgery, Allegheny General Hospital, Pittsburgh, PA 15212.

Received 7/12/96. Accepted 12/ 3/96.

This article has been cited by other articles:

				F. Cappuzzo, A. Marchetti, M. Skokan, E. Rossi, S. Gajapathy, L. Felicioni, M. del Grammastro, M. G. Sciarrotta, F. Buttitta, M. Incarbone, et al. Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients J. Clin. Oncol., April 1, 2009; 27(10): 1667 - 1674. [Abstract] [Full Text] [PDF]

				S. Fan, Q. Meng, J. J. Laterra, and E. M. Rosen Role of Src Signal Transduction Pathways in Scatter Factor-mediated Cellular Protection J. Biol. Chem., March 20, 2009; 284(12): 7561 - 7577. [Abstract] [Full Text] [PDF]

				A. Gupta, P. I. Karakiewicz, C. G. Roehrborn, Y. Lotan, A. R. Zlotta, and S. F. Shariat Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7385 - 7390. [Abstract] [Full Text] [PDF]

				L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]

				K. Okunishi, M. Dohi, K. Fujio, K. Nakagome, Y. Tabata, T. Okasora, M. Seki, M. Shibuya, M. Imamura, H. Harada, et al. Hepatocyte Growth Factor Significantly Suppresses Collagen-Induced Arthritis in Mice J. Immunol., October 15, 2007; 179(8): 5504 - 5513. [Abstract] [Full Text] [PDF]

				J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779. [Abstract] [Full Text] [PDF]

				T. A. D'Amico, K. R. Brooks, M.-B. M. Joshi, D. Conlon, J. Herndon II, R. P. Petersen, and D. H. Harpole Jr Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection Ann. Thorac. Surg., June 1, 2006; 81(6): 1982 - 1987. [Abstract] [Full Text] [PDF]

				K. Okunishi, M. Dohi, K. Nakagome, R. Tanaka, S. Mizuno, K. Matsumoto, J.-i. Miyazaki, T. Nakamura, and K. Yamamoto A Novel Role of Hepatocyte Growth Factor as an Immune Regulator through Suppressing Dendritic Cell Function J. Immunol., October 1, 2005; 175(7): 4745 - 4753. [Abstract] [Full Text] [PDF]

				Y. Ren, B. Cao, S. Law, Y. Xie, P. Y. Lee, L. Cheung, Y. Chen, X. Huang, H. M. Chan, P. Zhao, et al. Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas Clin. Cancer Res., September 1, 2005; 11(17): 6190 - 6197. [Abstract] [Full Text] [PDF]

				H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694. [Abstract] [Full Text] [PDF]

				K.-i. Nakashiro, S. Hara, Y. Shinohara, M. Oyasu, H. Kawamata, S. Shintani, H. Hamakawa, and R. Oyasu Phenotypic Switch from Paracrine to Autocrine Role of Hepatocyte Growth Factor in an Androgen-Independent Human Prostatic Carcinoma Cell Line, CWR22R Am. J. Pathol., August 1, 2004; 165(2): 533 - 540. [Abstract] [Full Text] [PDF]

				J. M. Siegfried, J. D. Luketich, L. P. Stabile, N. Christie, and S. R. Land Elevated Hepatocyte Growth Factor Level Correlates With Poor Outcome in Early-Stage and Late-Stage Adenocarcinoma of the Lung Chest, May 1, 2004; 125(5_suppl): 116S - 119S. [Full Text] [PDF]

				A. Iwasaki, M. Kuwahara, Y. Yoshinaga, and T. Shirakusa Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 443 - 448. [Abstract] [Full Text] [PDF]

				M. Wislez, N. Rabbe, J. Marchal, B. Milleron, B. Crestani, C. Mayaud, M. Antoine, P. Soler, and J. Cadranel Hepatocyte Growth Factor Production by Neutrophils Infiltrating Bronchioloalveolar Subtype Pulmonary Adenocarcinoma: Role in Tumor Progression and Death Cancer Res., March 15, 2003; 63(6): 1405 - 1412. [Abstract] [Full Text] [PDF]

				H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer Cancer Res., September 15, 2002; 62(18): 5210 - 5217. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				Y. To, M. Dohi, K. Matsumoto, R. Tanaka, A. Sato, K. Nakagome, T. Nakamura, and K. Yamamoto A Two-way Interaction between Hepatocyte Growth Factor and Interleukin-6 in Tissue Invasion of Lung Cancer Cell Line Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 220 - 226. [Abstract] [Full Text] [PDF]

				Y. Yu and G. Merlino Constitutive c-Met Signaling through a Nonautocrine Mechanism Promotes Metastasis in a Transgenic Transplantation Model Cancer Res., May 1, 2002; 62(10): 2951 - 2956. [Abstract] [Full Text] [PDF]

				J. M. Pilewski, T. S. Bumbalo III, A. G. Davis, and J. M. Siegfried Hepatocyte Growth Factor Promotes Tumor Growth in a Novel In Vivo Model of Human Lung Cancer Am. J. Respir. Cell Mol. Biol., May 1, 2001; 24(5): 556 - 562. [Abstract] [Full Text]

				M. Tokunou, T. Niki, K. Eguchi, S. Iba, H. Tsuda, T. Yamada, Y. Matsuno, H. Kondo, Y. Saitoh, H. Imamura, et al. c-MET Expression in Myofibroblasts : Role in Autocrine Activation and Prognostic Significance in Lung Adenocarcinoma Am. J. Pathol., April 1, 2001; 158(4): 1451 - 1463. [Abstract] [Full Text] [PDF]

				K.-i. Nakashiro, M. Okamoto, Y. Hayashi, and R. Oyasu Hepatocyte Growth Factor Secreted by Prostate-Derived Stromal Cells Stimulates Growth of Androgen-Independent Human Prostatic Carcinoma Cells Am. J. Pathol., September 1, 2000; 157(3): 795 - 803. [Abstract] [Full Text] [PDF]

				K. Gohji, M. Nomi, Y. Niitani, S. Kitazawa, A. Fujii, Y. Katsuoka, and M. Nakajima Independent Prognostic Value of Serum Hepatocyte Growth Factor in Bladder Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2963 - 2971. [Abstract] [Full Text] [PDF]

				K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]